
Crucell Announces PER.C6 Licensing Agreement with Novartis
Dutch biotechnology company Crucell N.V. (Leiden, the Netherlands, www.crucell.com) and Novartis Vaccines and Diagnostics, Inc. (Basel, Switzerland, www.novartis.com), have extended a nonexclusive research license agreement for PER.C6.
Dutch biotechnology company Crucell N.V. (Leiden, the Netherlands,
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.